Espero Pharma Announces Promotion Of Nitrolingual Pumpspray (Nitroglycerin Lingual Spray)

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today assumed the U.S. promotional responsibility for Nitrolingual^® Pumpspray, in an exclusive licensing agreement with G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”), a fully-integrated German pharmaceutical company. Jacksonville Pharmaceuticals, a wholly owned subsidiary of Espero Pharmaceuticals, has also assumed distribution and supply responsibility for the authorized generic version of Nitrolingual^® Pumpspray. Nitrolingual^® Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

“Espero is excited about commencing our commercial relationship with Pohl-Boskamp with Nitrolingual® Pumpspray as part of our portfolio of cardiovascular products”

“Espero is excited about commencing our commercial relationship with Pohl-Boskamp with Nitrolingual® Pumpspray as part of our portfolio of cardiovascular products,” said Quang Pham, CEO. “Pohl-Boskamp is an established worldwide leader in the short-acting nitrate market. More importantly, this partnership helps further enhance patient access to those suffering with angina due to coronary artery disease (CAD, the most common type of heart disease. It is the leading cause of death in the United States in both men and women according to The National Institute of Health.”

In November 2015, Espero Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for its nitroglycerin sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The FDA has set an action date of June 10, 2016 to complete its review, as per the Prescription Drug User Fee Act.

Espero & Jacksonville Pharmaceuticals

Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Fla., is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories. Jacksonville Pharmaceuticals, Inc. is a generic pharmaceutical company focused on distributing and marketing select generic pharmaceutical products.

G. Pohl-Boskamp GmbH & Co KG

Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for 175 years with commercialized products in more than 45 countries. Through close collaboration with its partners abroad, Pohl-Boskamp focuses on developing and marketing products that positively impact patients’ quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology. For more information visit http://www.pohl-boskamp.com/en/.